On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a hard-to-treat cancer that strikes more than 31,000 Americans a year. The approval rests on Phase 3 data showing patients lived a median of 26.4 months, more than two years, the longest survival benchmark yet reported for an immunotherapy-based regimen in this setting regardless of a patient’s PD-L1 status. For a company already riding hematology momentum, it adds a genuine second growth engine.
More Than Two Years
The HERIZON-GEA-01 trial behind the approval randomized 914 patients across roughly 300 sites in more than 30 countries, a scale that lends weight to the result. Median progression-free survival reached 12.4 months against 8.1 months for the prior standard of trastuzumab plus chemotherapy, and even patients with PD-L1-negative tumors, historically the hardest to treat, lived a median of 29.7 months versus 15.8 months on the older regimen. Roughly one in five GEA patients carries the HER2-positive mutation, and fewer than 40% of them survive two years in the United States today, so a regimen pushing median survival past that mark closes a real gap.
That approval lands on top of a hematology business already accelerating. In its August 5, 2026 earnings call, management reported second-quarter revenue of $1.7 billion, up 30% year over year, while BRUKINSA’s global sales climbed 31% to $1.2 billion on the highest pace of new patient starts since launch. Management raised full-year revenue guidance by $300 million to a range of $6.6 billion to $6.8 billion and lifted its operating income outlook by $250 million. The Phase 3 MANGROVE study added more fuel, posting a hazard ratio of 0.57 for a rituximab combination against the standard bendamustine regimen in frontline mantle cell lymphoma, a disease diagnosed in roughly 21,000 patients a year. A real-world analysis of more than 10,500 Medicare patients found BRUKINSA cut the risk of death by 24% and 36% against acalabrutinib and ibrutinib, respectively.
Cracks Beneath The Momentum
Not every readout landed cleanly. In the CELESTIAL 301 study, the zanubrutinib-sonrotoclax combination failed to reach statistical superiority over the venetoclax-obinutuzumab regimen on its undetectable minimal residual disease measure, even as the trial continues toward its progression-free survival endpoint. Management argued that undetectable MRD does not reliably predict PFS across different drug classes, but the miss is a reminder that BeOne’s newer combinations still have to prove themselves against an established rival.
Elsewhere, the Amgen in-licensed portfolio that contributed $157 million in the quarter faces biosimilar competition for XGEVA that CFO Aaron Rosenberg said could weigh on results beyond this year. Operating expenses rose 13% to $1.2 billion as the company pushes five solid tumor programs toward pivotal trials, and a $60 million tax audit settlement dented reported net income even as adjusted operating income grew more than 80%. TEVIMBRA’s $229 million in quarterly sales came despite what management called steep competition in China, its largest overseas market, and 7 percentage points of that market’s growth traced to currency strength rather than underlying demand. None of this undoes the GEA approval, but it shows a company juggling a lot of moving parts at once.
A Rich Price For Growth
Hedge fund ownership slipped from 27 funds to 24 in the most recent quarter, a modest pullback rather than a rush for the exits. Short interest sits at just 1.59% of the float, showing little organized skepticism toward the stock. As of September 1, shares trade at a forward price-to-earnings ratio of 46.73, a multiple that assumes the GEA approval and BRUKINSA’s growth keep compounding without a stumble. That mix, light shorting alongside a rich multiple, leaves little room for disappointment to go unpunished.
Where BeOne Goes From Here
BeOne Medicines now has two engines pulling in the same direction: a hematology franchise still setting records and a solid tumor pipeline that just delivered its first major oncology win. For the growth story to keep compounding, the GEA approval needs to translate into real prescriptions while BRUKINSA keeps taking share and MANGROVE data mature toward its own approval.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
